Guggenheim Reaffirms Buy Rating for Merus (NASDAQ:MRUS)

Merus (NASDAQ:MRUS - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at Guggenheim in a note issued to investors on Wednesday,Benzinga reports.

Several other equities analysts have also weighed in on the stock. Citigroup increased their price objective on shares of Merus from $89.00 to $97.00 and gave the company a "buy" rating in a research report on Monday, December 9th. The Goldman Sachs Group began coverage on shares of Merus in a research note on Thursday, November 21st. They set a "buy" rating and a $73.00 price objective on the stock. UBS Group began coverage on shares of Merus in a report on Thursday, October 24th. They issued a "buy" rating and a $72.00 target price for the company. Needham & Company LLC reissued a "buy" rating and issued a $85.00 target price on shares of Merus in a report on Monday, December 9th. Finally, Wells Fargo & Company began coverage on shares of Merus in a report on Friday, February 7th. They issued an "overweight" rating and a $91.00 target price for the company. One research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $85.92.

Merus Stock Performance

Shares of MRUS stock traded down $0.10 during trading on Wednesday, reaching $40.20. The company's stock had a trading volume of 362,709 shares, compared to its average volume of 655,991. The business has a fifty day moving average price of $41.55 and a 200-day moving average price of $47.17. Merus has a one year low of $37.77 and a one year high of $61.61.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MRUS. Wells Fargo & Company MN raised its holdings in Merus by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 300 shares during the last quarter. Avior Wealth Management LLC bought a new position in Merus during the 4th quarter worth approximately $76,000. nVerses Capital LLC grew its position in shares of Merus by 750.0% during the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company's stock worth $85,000 after buying an additional 1,500 shares during the period. US Bancorp DE acquired a new stake in shares of Merus during the 3rd quarter worth approximately $103,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Merus by 24.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company's stock worth $118,000 after buying an additional 489 shares during the period. Institutional investors own 96.14% of the company's stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.